{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T01:53:53Z","timestamp":1791942833134,"version":"4.3.4"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T00:00:00Z","timestamp":1704153600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T00:00:00Z","timestamp":1704153600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Medical cannabis use and public acceptance in the United States have increased over the past 25\u00a0years. However, access to medical cannabis remains limited, particularly for underserved populations. To understand how patients experience medical cannabis accessibility, we measured medical cannabis use and barriers to use after medical cannabis certification in an urban safety-net academic medical center.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective cohort study among patients seen in Montefiore\u2019s Medical Cannabis Program (MMCP) from 2017 to 2019. Patient demographic and clinical characteristics, as well purchase history of medical cannabis, were extracted from electronic medical records. We also administered a phone questionnaire to a subset of patients to assess usage patterns, effectiveness, and barriers to medical cannabis use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 562 patients who were newly certified for medical cannabis between 2017 and 2019, 45% purchased medical cannabis, while 55% did not. Patients who purchased medical cannabis were more likely to be white and have private insurance or Medicare. Unregulated cannabis use and current tobacco use were less common among those who purchased medical cannabis. In multivariable logistic regression analysis, unregulated cannabis use remained negatively associated with purchasing medical cannabis. Patients reported that affordability and dispensary accessibility were their main barriers to purchasing medical cannabis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Among patients certified for medical cannabis use, fewer than half purchased medical cannabis after certification. Improving access to medical cannabis is crucial for ensuring equitable access to regulated cannabis, and to reducing unregulated cannabis use.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12954-023-00919-2","type":"journal-article","created":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T14:02:58Z","timestamp":1704204178000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Available but inaccessible: patient experiences during the first 2\u00a0years of a primary care-based medical cannabis program at an academic medical center"],"prefix":"10.1186","volume":"21","author":[{"given":"Eloise W.","family":"Freitag","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuval","family":"Zolotov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayabhargav","family":"Annam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaqueline","family":"Labins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaclyn M.","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syeda Masharab","family":"Jillani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia H.","family":"Arnsten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepika E.","family":"Slawek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,2]]},"reference":[{"key":"919_CR1","unstructured":"Green TV. Americans overwhelmingly say marijuana should be legal for medical or recreational use [Internet]. Pew Research Center. 2021 [cited 2023 Jun 5]. Available from: https:\/\/www.pewresearch.org\/short-reads\/2022\/11\/22\/americans-overwhelmingly-say-marijuana-should-be-legal-for-medical-or-recreational-use\/"},{"key":"919_CR2","unstructured":"Ortiz NR, Preuss CV. Controlled Substance Act. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023;24. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK574544\/"},{"issue":"6","key":"919_CR3","doi-asserted-by":"publisher","first-page":"3336","DOI":"10.3390\/ijerph19063336","volume":"19","author":"J Donnelly","year":"2022","unstructured":"Donnelly J, Young M, Marshall B, Hecht ML, Saldutti E. Public health implications of cannabis legalization: an exploration of adolescent use and evidence-based interventions. Int J Environ Res Public Health. 2022;19(6):3336.","journal-title":"Int J Environ Res Public Health"},{"key":"919_CR4","unstructured":"National Conference of State Legislatures (NCSL). State Medical Cannabis Laws [Internet]. 2023;22. Available from: https:\/\/www.ncsl.org\/health\/state-medical-cannabis-laws (Accessed: 17 July 2023)."},{"key":"919_CR5","unstructured":"New York (.gov). Assessment of the Potential Impact of Regulated Marijuana in New York State. 2018;13. Available from: https:\/\/cannabis.ny.gov\/system\/files\/documents\/2019\/03\/executivesummary07-13-18.pdf"},{"key":"919_CR6","doi-asserted-by":"publisher","first-page":"103202","DOI":"10.1016\/j.drugpo.2021.103202","volume":"94","author":"EL Richard","year":"2021","unstructured":"Richard EL, Althouse AD, Arnsten JH, Bulls HW, Kansagara D, Kerbag MN, et al. How medical are states\u2019 medical cannabis policies?: Proposing a standardized scale. Int J Drug Policy. 2021;94:103202.","journal-title":"Int J Drug Policy"},{"key":"919_CR7","unstructured":"New York State Department of Health (2018). Medical Use of Marijuana: Two-Year Report [PDF]. Albany, NY: New York State Department of Health. Available from: https:\/\/cannabis.ny.gov\/system\/files\/documents\/2023\/03\/medical-use-of-marijuana-two-year-report-9-27-18.pdf."},{"issue":"2","key":"919_CR8","first-page":"CAT-21","volume":"3","author":"J Ross","year":"2022","unstructured":"Ross J, Yamada JM, Slawek DE, Starrels JL, Cunningham CO, Arnsten JH. Increasing access to safe medical cannabis. NEJM Catal Innov Care Deliv. 2022;3(2):CAT-21.","journal-title":"NEJM Catal Innov Care Deliv"},{"key":"919_CR9","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.pmedr.2014.12.006","volume":"2","author":"B Fischer","year":"2015","unstructured":"Fischer B, Murphy Y, Kurdyak P, Goldner E, Rehm J. Medical marijuana programs\u2014why might they matter for public health and why should we better understand their impacts? Prevent Med Rep. 2015;2:53\u20136.","journal-title":"Prevent Med Rep"},{"issue":"1","key":"919_CR10","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1186\/s12889-022-13076-1","volume":"22","author":"CO Cunningham","year":"2022","unstructured":"Cunningham CO, Zhang C, Hollins M, Wang M, Singh-Tan S, Joudrey PJ. Availability of medical cannabis services by racial, social, and geographic characteristics of neighborhoods in New York: a cross-sectional study. BMC Public Health. 2022;22(1):671.","journal-title":"BMC Public Health"},{"key":"919_CR11","doi-asserted-by":"crossref","unstructured":"Singer A, Kosowan L, Muthumuni D, Katz A, Zafari H, Zulkernine F, et al. Characterizing primary care patients with posttraumatic stress disorder using electronic medical records: a retrospective cross-sectional study. Fam Pract. 2022;cmac139.","DOI":"10.1093\/fampra\/cmac139"},{"issue":"1","key":"919_CR12","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1477-7517-10-2","volume":"10","author":"JL Bottorff","year":"2013","unstructured":"Bottorff JL, Bissell LJ, Balneaves LG, Oliffe JL, Capler NR, Buxton J. Perceptions of cannabis as a stigmatized medicine: a qualitative descriptive study. Harm Reduct J. 2013;10(1):2.","journal-title":"Harm Reduct J"},{"key":"919_CR13","unstructured":"Vireo Health. Do Discounted Vouchers for Medical Cannabis Reduce Opioid Use in Adults With Pain: A Randomized Controlled Trial (The ReLeaf-V Study) [Internet]. clinicaltrials.gov; 2022 [cited 2023 Jul 16]. Report No.: NCT04495725. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04495725"},{"issue":"6","key":"919_CR14","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1111\/dar.12275","volume":"34","author":"N Lau","year":"2015","unstructured":"Lau N, Sales P, Averill S, Murphy F, Sato SO, Murphy S. A safer alternative: Cannabis substitution as harm reduction. Drug Alcohol Rev. 2015;34(6):654\u20139.","journal-title":"Drug Alcohol Rev"},{"issue":"10208","key":"919_CR15","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1016\/S0140-6736(19)31789-1","volume":"394","author":"W Hall","year":"2019","unstructured":"Hall W, Stjepanovi\u0107 D, Caulkins J, Lynskey M, Leung J, Campbell G, et al. Public health implications of legalising the production and sale of cannabis for medicinal and recreational use. Lancet (London, England). 2019;394(10208):1580\u201390.","journal-title":"Lancet (London, England)"},{"key":"919_CR16","first-page":"689","volume":"50","author":"S Bender","year":"2016","unstructured":"Bender S. The colors of cannabis: race and Marijuana. UC Davis L Rev. 2016;50:689\u2013706.","journal-title":"UC Davis L Rev"},{"issue":"1","key":"919_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13643-017-0541-4","volume":"6","author":"CI Valencia","year":"2017","unstructured":"Valencia CI, Asaolu IO, Ehiri JE, Rosales C. Structural barriers in access to medical marijuana in the USA\u2014a systematic review protocol. Syst Rev. 2017;6(1):1\u20138.","journal-title":"Syst Rev"},{"issue":"4","key":"919_CR18","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.drugpo.2014.02.009","volume":"25","author":"L Belle-Isle","year":"2014","unstructured":"Belle-Isle L, Walsh Z, Callaway R, Lucas P, Capler R, Kay R, Holtzman S. Barriers to access for Canadians who use cannabis for therapeutic purposes. Int J Drug Policy. 2014;25(4):691\u20139.","journal-title":"Int J Drug Policy"},{"key":"919_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12954-020-00377-0","volume":"17","author":"N Lintzeris","year":"2020","unstructured":"Lintzeris N, Mills L, Suraev A, Bravo M, Arkell T, Arnold JC, Benson MJ, McGregor IS. Medical cannabis use in the Australian community following introduction of legal access: the 2018\u20132019 Online Cross-Sectional Cannabis as Medicine Survey (CAMS-18). Harm Reduct J. 2020;17:1\u20132.","journal-title":"Harm Reduct J"},{"issue":"12","key":"919_CR20","doi-asserted-by":"publisher","first-page":"4034","DOI":"10.1007\/s10461-022-03729-y","volume":"26","author":"T Krulic","year":"2022","unstructured":"Krulic T, Brown G, Bourne A. A scoping review of peer navigation programs for people living with HIV: form, function and effects. AIDS Behav. 2022;26(12):4034\u201354.","journal-title":"AIDS Behav"},{"issue":"10","key":"919_CR21","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1089\/aid.2020.0013","volume":"36","author":"KA McManus","year":"2020","unstructured":"McManus KA, Killelea A, Honeycutt E, An Z, Keim-Malpass J. Assisters succeed in insurance navigation for people living with HIV and people at increased risk of HIV in a complex coverage landscape. AIDS Res Hum Retroviruses. 2020;36(10):842\u201351.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"8","key":"919_CR22","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1089\/apc.2022.0062","volume":"36","author":"M Padilla","year":"2022","unstructured":"Padilla M, Carter B, Gutierrez M, Fagan J. The boundary of HIV care: barriers and facilitators to care engagement among people with HIV in the United States. AIDS Patient Care STDS. 2022;36(8):321\u201331.","journal-title":"AIDS Patient Care STDS"},{"issue":"7","key":"919_CR23","doi-asserted-by":"publisher","first-page":"945","DOI":"10.7326\/M22-0217","volume":"175","author":"KF Boehnke","year":"2022","unstructured":"Boehnke KF, Dean O, Haffajee RL, Hosanagar AUS. Trends in registration for medical cannabis and reasons for use from 2016 to 2020: an observational study. Ann Intern Med. 2022;175(7):945\u201351.","journal-title":"Ann Intern Med"},{"key":"919_CR24","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.drugalcdep.2015.11.015","volume":"159","author":"BJ Fairman","year":"2016","unstructured":"Fairman BJ. Trends in registered medical marijuana participation across 13 US states and District of Columbia. Drug Alcohol Depend. 2016;159:72\u20139.","journal-title":"Drug Alcohol Depend"},{"key":"919_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s42238-020-00038-w","volume":"2","author":"VK Mahabir","year":"2020","unstructured":"Mahabir VK, Merchant JJ, Smith C, Garibaldi A. Medical cannabis use in the United States: a retrospective database study. J Cannabis Res. 2020;2:1\u20133.","journal-title":"J Cannabis Res"},{"issue":"5","key":"919_CR26","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1177\/0269881117699616","volume":"31","author":"BJ Piper","year":"2017","unstructured":"Piper BJ, DeKeuster RM, Beals ML, Cobb CM, Burchman CA, Perkinson L, Lynn ST, Nichols SD, Abess AT. Substitution of medical cannabis for pharmaceutical agents for pain, anxiety, and sleep. J Psychopharmacol. 2017;31(5):569\u201375.","journal-title":"J Psychopharmacol"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-023-00919-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-023-00919-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-023-00919-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T02:07:47Z","timestamp":1704247667000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-023-00919-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,2]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["919"],"URL":"https:\/\/doi.org\/10.1186\/s12954-023-00919-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3243516\/v1","asserted-by":"object"}]},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,2]]},"assertion":[{"value":"8 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was considered exempt from informed consent by the Albert Einstein College of Medicine Institutional Review Board because of the study type (\u201cTests, surveys, interviews, or observation [identifiable]\u201d). This study was considered exempt by the _Albert Einstein College of Medicine Institutional Review Board and study procedures were performed in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Slawek and Dr. Arnsten reported grants from the National Institutes of Health and from the Laura and Jane Arnold Foundation outside the submitted work. Ms. Freitag, and Drs. Zolotov, Annam, Labins, Yamada, and Jillani report no other disclosures.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1"}}